Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 4/20 | 0.71 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 5/20 | 0.51 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | SGK1 | O00141 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.46 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487615 | 0.94 | CDK8 (0.68) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL12764139 | 0.86 | CDK8 (0.85) | CDK8AXLTNIKCLK1DYRK1A | |
| SCHEMBL13745464 | 0.83 | CDK8 (1.00) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL8320115 | 0.83 | CDK8 (0.84) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL8256242 | 0.83 | CDK8 (0.72) | CDK8AXLTNIKCLK1DYRK1A | |
| SCHEMBL12763457 | 0.82 | CDK8 (0.79) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL8313358 | 0.81 | CDK8 (0.77) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL8320362 | 0.81 | CDK8 (0.77) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL8313393 | 0.81 | CDK8 (0.77) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL13745361 | 0.81 | CDK8 (0.77) | CDK8CCNT1CCNA2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | CDK8 1731/4885CCNT1 3711/4885CCNA2 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.